You are here

Drug Discovery

 

CRUK Therapeutic Discovery Laboratories (CRUK-TDL) is the in-house CRUK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry. Based at the Babraham Research Campus, Cambridge, and the London Bioscience Innovation Centre, CRUK-TDL comprises over 80 staff from both industrial and academic backgrounds.

In recent years, CRUK-TDL has established successful alliances with AstraZeneca, Teva Pharmaceuticals, FORMA Therapeutics, Merck KGaA, and LifeArc (formerly MRCT). 

Cancer Research UK funds a number of research institutes and drug discovery programmes across the UK and CRT has exclusive commercialisation rights to the wealth of oncology-related discoveries arising from these institutes.

  • CRUK-TDL Discovery Laboratories

    CRUK-TDL is the in-house CRUK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry. It has expertise spanning cancer target validation and disease positioning, assay development and HTS, protein crystallography, medicinal chemistry, PK-PD and cancer models. Through its alliance approach, CRUK-TDL aligns these key skills with internationally competitive academic research and the development capabilities of industry partners to maximise cancer patient benefit.

    This themed approach drives strong partner engagement, teamwork across academia and industry, high quality target selection and efficiency in drug discovery project prosecution. CRUK-DL has an impressive track record establishing and executing five major alliances in recent years and, with its industry and academic partners, demonstrating tangible outcomes.

    CRUK-TDL works with the academic network, potential commercial partners and Cancer Research UK’s Drug Discovery Committee to prioritise areas for evaluation and early portfolio development. Its remit is to deliver first-in-class breakthrough therapies for cancer patients.

    Visit the CRUK-TDL website

  • CRUK Drug Discovery

    Cancer Research UK has an established history of successful drug discovery and development, having contributed to the discovery or clinical trials of nearly 50 drugs now in clinical development.

    Translational research is an expanding part of CRUK's portfolio, reflecting efforts to ensure its research delivers patient benefit. The charity drives specific initiatives to support translational research, including investing more than £20 million in its core drug discovery programmes.


    The CRUK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR CTU). Read more.


    The CRUK Drug Discovery Unit at the Cancer Research UK Manchester Institute. Read more.


    The Beatson Drug Discovery Unit at the Cancer Research UK Beatson Institute. Read more.


     

CRUK-TDL Discovery Laboratories Open

CRUK-TDL is the in-house CRUK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry. It has expertise spanning cancer target validation and disease positioning, assay development and HTS, protein crystallography, medicinal chemistry, PK-PD and cancer models. Through its alliance approach, CRUK-TDL aligns these key skills with internationally competitive academic research and the development capabilities of industry partners to maximise cancer patient benefit.

This themed approach drives strong partner engagement, teamwork across academia and industry, high quality target selection and efficiency in drug discovery project prosecution. CRUK-DL has an impressive track record establishing and executing five major alliances in recent years and, with its industry and academic partners, demonstrating tangible outcomes.

CRUK-TDL works with the academic network, potential commercial partners and Cancer Research UK’s Drug Discovery Committee to prioritise areas for evaluation and early portfolio development. Its remit is to deliver first-in-class breakthrough therapies for cancer patients.

Visit the CRUK-TDL website

CRUK Drug Discovery Open

Cancer Research UK has an established history of successful drug discovery and development, having contributed to the discovery or clinical trials of nearly 50 drugs now in clinical development.

Translational research is an expanding part of CRUK's portfolio, reflecting efforts to ensure its research delivers patient benefit. The charity drives specific initiatives to support translational research, including investing more than £20 million in its core drug discovery programmes.


The CRUK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR CTU). Read more.


The CRUK Drug Discovery Unit at the Cancer Research UK Manchester Institute. Read more.


The Beatson Drug Discovery Unit at the Cancer Research UK Beatson Institute. Read more.